FIG 3.
bNAb NIH45-46G54W potently inhibits replication-competent HIV-1NL43-ΔR1 strains harboring escape mutations to BMS-626529. (a) Schematic of the infection of C8166 T cells with wild-type or mutant HIV-1NL43-ΔR1 and treatment with BMS-626529 or bNAb, which was added to cell supernatant at 1 nM every 6 days. D, day. (b) Replication curves of WT/mutant HIV-1NL43-ΔR1 with the indicated treatment. RLU levels were determined by infecting TZM-bl cells with cell supernatant collected at the indicated time points after infection. Data represent results of two independent experiments performed in duplicate. (c) Schematic of the D0 infection of C8166 T cells with wild-type or mutant HIV-1NL43-ΔR1 and D0 treatment with 1 nM BMS-626529 or bNAb. (d) Replication curves of mutant NL43-ΔR1 in the presence of BMS-626529 or bNAb, as indicated. RLU levels were determined by infecting TZM-bl cells with cell supernatant collected at the indicated time points postinfection. Data represent results of two independent experiments performed in duplicate.